Oxiperomide

Oxiperomide
Clinical data
Routes of; administration	Oral
Identifiers
	IUPAC name 3-[1-(2-phenoxyethyl)piperidin-4-yl]-1H-benzimidazol-2-one;
CAS Number	5322-53-2;
PubChem CID	68634;
ChemSpider	61893;
UNII	WRO75M6RW2;
KEGG	D02676;
ChEMBL	ChEMBL2059304;
CompTox Dashboard (EPA)	DTXSID30201306 ;
Chemical and physical data
Formula	C20H23N3O2
Molar mass	337.423 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCOC4=CC=CC=C4;
	InChI InChI=1S/C20H23N3O2/c24-20-21-18-8-4-5-9-19(18)23(20)16-10-12-22(13-11-16)14-15-25-17-6-2-1-3-7-17/h1-9,16H,10-15H2,(H,21,24); Key:NVDBBGBUTKLRSN-UHFFFAOYSA-N;

Oxiperomide is an antipsychotic.[1] Clinical trials demonstrated that it can reduce dyskinesia in patients with Parkinson's disease who are taking dopamine agonists without increasing Parkinsonian symptoms. It does this by selectively antagonizing dopamine receptors.[2][3] Further development of this drug is not available. It appears to have never been marketed.

References

Elks J (1990). "Oxiperomide". The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Dordrecht: Springer. ISBN 978-1-4757-2085-3.
Bédard P, Parkes JD, Marsden CD (April 1978). "Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias". British Medical Journal. 1 (6118): 954–956. doi:10.1136/bmj.1.6118.954. PMC 1603806. PMID 638546.
Casey DE, Gerlach J (March 1980). "Oxiperomide in tardive dyskinesia". Journal of Neurology, Neurosurgery, and Psychiatry. 43 (3): 264–267. doi:10.1136/jnnp.43.3.264. PMC 490519. PMID 7373324.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.